ICER releases list of potential review topics in 2018

ICER releases list of potential review topics in 2018 PharmacoEconomics & Outcomes News 784, p3 - 12 Aug 2017 ICER releases list of potential review topics in 2018 The Institute for Clinical and Economic Review (ICER) has published a preliminary list of prescription drug review topics for 2018, which includes some for cancers, migraine, and cystic fibrosis. ICER draws its list of topics for review from its horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public. Topic selection criteria includes the projected timing and likelihood of FDA approval, and whether a review of the evidence is likely to result in specific actions to improve clinical practice and/or policy. The list, which may change, includes: voretigene neparvovec [Spark Therapeutics] for vision loss associated with biallelic RPE65-mediated retinal disease; axicabtagene ciloleucel [Kite Pharmaceuticals] and tisagenlecleucel-t [Novartis] for B-cell leukemia and lymphoma; apalutamide [Johnson & Johnson] for prostate cancer CTP-modified human growth hormone [Opko/ Pfizer] for short stature/growth hormone deficiency; damoctocog-α pegol [Bayer], emicizumab [Roche] for haemophilia type A; erenumab [Amgen], fremanezumab [Teva], and galcanezumab [Eli Lilly] for migraine and other headaches; lanadelumab [Shire] for hereditary angioedema; larotrectinib [LOXO Oncology/Array BioPharma] for solid tumors expressing a specific biomarker; and, tezacaftor in combination with ivacaftor [Vertex] for cystic fibrosis. The next topic announcement is expected mid- August. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Announces Potential Topics for Review in 2018. Internet Document : 26 Jul 2017. Available from: URL: https://icer-review.org/announcements/icer-topic- selection-2018/ 803261766 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

ICER releases list of potential review topics in 2018

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/icer-releases-list-of-potential-review-topics-in-2018-r8rjcD29Ve
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4214-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p3 - 12 Aug 2017 ICER releases list of potential review topics in 2018 The Institute for Clinical and Economic Review (ICER) has published a preliminary list of prescription drug review topics for 2018, which includes some for cancers, migraine, and cystic fibrosis. ICER draws its list of topics for review from its horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public. Topic selection criteria includes the projected timing and likelihood of FDA approval, and whether a review of the evidence is likely to result in specific actions to improve clinical practice and/or policy. The list, which may change, includes: voretigene neparvovec [Spark Therapeutics] for vision loss associated with biallelic RPE65-mediated retinal disease; axicabtagene ciloleucel [Kite Pharmaceuticals] and tisagenlecleucel-t [Novartis] for B-cell leukemia and lymphoma; apalutamide [Johnson & Johnson] for prostate cancer CTP-modified human growth hormone [Opko/ Pfizer] for short stature/growth hormone deficiency; damoctocog-α pegol [Bayer], emicizumab [Roche] for haemophilia type A; erenumab [Amgen], fremanezumab [Teva], and galcanezumab [Eli Lilly] for migraine and other headaches; lanadelumab [Shire] for hereditary angioedema; larotrectinib [LOXO Oncology/Array BioPharma] for solid tumors expressing a specific biomarker; and, tezacaftor in combination with ivacaftor [Vertex] for cystic fibrosis. The next topic announcement is expected mid- August. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Announces Potential Topics for Review in 2018. Internet Document : 26 Jul 2017. Available from: URL: https://icer-review.org/announcements/icer-topic- selection-2018/ 803261766 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off